India Glycols Limited · NSE:INDIAGLYCO
India Glycols — Q4 & FY22 Earnings Presentation
33 slides from India Glycols's earnings presentation, May 30, 2022
Slide 1: Regulation 30 disclosure letter to stock exchanges
0 ~c£ RT/fi(' ,._«J -Y,,. J: 0 \~~v) ISO 9001 INDIA GLYCOLS LIMITED ISO 14001 ; ISO 45001 ; ISO 500~>1 Plot No. 2-B, Sector -126, NOIDA-201304, Dist!. Gautam Budh Nagar, Uttar Pradesh, Tel.: +91 120 6860000, 3090100, 3090200 Fax : +91 120 3090111, 3090211 E-mail: i lho@indiaglycols .com . Website :
Slide 2: Investor Presentation Q4 & FY22
Investor Presentation Q4 & FY22
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation and the following discussion may contain “forward looking statements” by India Glycols Limited (“IGL” or the company) that are not historical in nature. These forward looking statements, which may include statements relating to future results of operations, f
Slide 4: Q4 & FY22 Performance
Q4 & FY22 Performance INDIA GLYCOLS LIMITED
Slide 5: Performance Overview – FY22 vs FY21
Performance Overview – FY22 vs FY21 Gross Turnover Net Turnover 6,623 Cr 3,104 Cr 22% 3% EBITDA EBIDTA Margin PAT 298 Cr 340 Cr 20% 9.6% 158% Resilient performance in a challenging year • Significant revenue and margin growth (recovery) particularly in the BSPC business • 12 month vs 3 month of Bio-
Slide 6: Performance Overview – Q4FY22 vs Q4FY21
Performance Overview – Q4FY22 vs Q4FY21 Gross Turnover Net Turnover 1,494 Cr 642 Cr 18% 34% EBITDA EBIDTA Margin PAT 84 Cr 71 Cr 35% 13.4% 6% Impact • EOD business transferred to JV • Sharp escalation in Energy and Feedstock prices 5
Slide 7: Performance Overview – FY22 vs FY21 – Continued Business
Performance Overview – FY22 vs FY21 – Continued Business Gross Turnover Net Turnover 6,601 Cr 2,868 Cr 22% 24% EBITDA EBIDTA Margin PAT 277 Cr 330 Cr 2% 9.6% 202% Health growth in all three segments in a challenging operating environment– BSPC, Potable Spirits, Ennature Biopharma Combined effect of
Slide 8: Performance Overview – Q4FY22 vs Q4FY21 – Continued Business
Performance Overview – Q4FY22 vs Q4FY21 – Continued Business Gross Turnover Net Turnover 1,494 Cr 642 Cr 7% 15% EBITDA EBIDTA Margin PAT 84 Cr 67 Cr 13% 13.0% 4% Slower growth in the fourth quarter, and impact of Covid, increased feedstock and energy costs impacted operating margin as well as sales.
Slide 9: Highlights – FY 2021-22
Highlights – FY 2021-22 JV formed with Clariant for the Bio based EOD business effective 30 Jun 2021. Transition completed as per plan and JV functioning well. Global ICIS Award for Sustainability with together with Unilever and Lanzatech Unprecedented escalation in Feedstock and Energy prices putti
Slide 10: Business Segment Highlights
Business Segment Highlights Bio-based Specialities and Potable Spirits Ennature Biopharma Performance Chemicals Excellent bounce back in sales and Healthy sales growth, margins impacted Moderate growth, margins under margins due to sharp escalation in ENA costs pressure in some exports Pressure from
Slide 11: Challenging Operating Environment
Challenging Operating Environment High degree of uncertainty in the macros economic environment Covid Impact continues in global and domestic market Unprecedented increase in input costs faced by industry, our War Covid suppliers, customers o Sharp increase in feedstock prices e.g. Ethanol o D
Slide 12: Financial Summary - Consolidated
Financial Summary - Consolidated Particulars (In INR Cr) Q4FY22 Q4FY21 Y-o-Y (%) Q3FY22 Q-o-Q (%) FY22 FY21 Y-o-Y (%) Revenue from operations (net of excise) 642 752 (14.6%) 795 (19.2%) 2,868 2,317 23.8% Other Income 5 10 (52.6%) 7 (31.4%) 22 15 41.2% Total Income 647 762 (15.1%) 802 (19.3%) 2,890 2
Slide 13: Segment Performance - Consolidated
Segment Performance - Consolidated 6% 5% (In INR Cr) Q4FY22 Q4FY21 % Change FY22 FY21 % YoY Bio-based Specialities and Performance Chemicals (BSPC) 26% 27% Net Revenue 429 520 (17.3%) 2,026 1,532 32.3% 67% 69% EBIT 43 46 (5.3%) 121 66 82.2% % margin 10.1% 8.8% 128 bps 6.0% 4.3% 163 bps Q4FY22 Q4FY21
Slide 14: Company Overview
Company Overview INDIA GLYCOLS LIMITED
Slide 15: IGL at a Glance
IGL at a Glance Go Green Diversified product portfolio Global Standards with inherent synergies Compliance with stringent global 1st in the world to use Innovative Green Technologies to manufacture Bio-based Specialties, Bio-Polymers, standards of plant operations, bio-based ethylene oxide & Potable
Slide 16: Key Milestones
Key Milestones Gorakhpur Glycol E 2 Distillery CL Textile Formulation JV Sulphation Clariant Thiocolchicoside First Bio-polymers MEG Dehradun US Nicotine Distillery EO Purification Green Solvents ENA 600 TPD Ennature Subsidiary Expansion 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 20
Slide 17: Portfolio Leading in Bio-based Ingredients and Performance Chemicals
Portfolio Leading in Bio-based Ingredients and Performance Chemicals Bio-based Specialities Segments And Performance Potable Spirits (PS) Ennature Biopharma Chemicals (BSPC) Revenue Mix Net revenue share : 71% Net revenue share : 24% Net revenue share : 5% (Consol. FY22) 1. Bio-based Glycols (MEG, D
Slide 18: JV with Clariant: Leaders in bio-based ethoxylates and derivatives
JV with Clariant: Leaders in in bio-based ethoxylates and derivatives Promoters Public 1 - Shareholding Combining production and distribution capacity, as 61.01% 1 38.99% 1 on 30th June 2021 the joint venture is expected to become a leading supplier of renewable materials to the rapidly growing FY20
Slide 19: Leveraging synergies to create value–integrated manufacturing
Leveraging synergies to create value–integrated manufacturing for bio-based products Potable Spirit Grain ENA Power Alcohol IGD O2, N2, Ar Brands Ind Gr. CO2 Distillery O2 ASU EO-CO2 mix Business transferred to JV with Clariant Green Molasses Distillery Bio-Ethanol Bio-Ethylene Bio- EO Bio-EODs Perf
Slide 20: Capabilities
Manufacturing Capabilities Kashipur Gorakhpur Dehradun 56-acre state of art distillation 300-acre state of art integrated manufacturing complex 160,000 sq. feet state of art facility and bottling complex Fermentation – Molasses and Grain Based Fermentation High Purity Extraction Ethanol Distillation
Slide 21: R&D: Creating value through New Product Development
R&D: Creating value through New Product Development; focus on Green Chemistry 1 Focus on NPD, designing products for the future in collaboration with our reputed customers 2 DSIR Recognized R&D at Dehradun and Kashipur 3 Exploiting available feed stocks of Bio-Alcohol, Smart Alcohol, Ethylene Oxide,
Slide 22: Business Segments
Business Segments
Slide 23: Bio-based Specialities and Performance Chemicals (BSPC)
Bio-based Specialities and Performance Chemicals (BSPC) First in the world to manufacture ethylene oxide and glycols from bio-based feedstocks e.g. Molasses, Grain Largest manufacturer of Bio-based glycols and Bio-based Ethylene Oxide made from renewable feedstock i.e. Molasses Products for a
Slide 24: Potable Spirits
Potable Spirits License for operations and sale of Country Liquor in the States of Uttar Pradesh and Uttarakhand. Also operates and sells Indian Made Foreign Liquor (“IMFL”) from its own unit and few tie-up units Company brands are available in the states of Uttarakhand, Uttar Pradesh, Delhi and
Slide 25: Ennature Biopharma
Ennature Biopharma Operates in the space of Nutraceuticals, Phytochemicals & health supplement ingredients. One of the leaders in Complex phytochemicals chemistry in India Global leader in Thiocolchicoside, a highly potent muscle relaxant API Advanced production capabilities, including organic
Slide 26: IGL - Catering to diverse end markets
IGL - Catering to diverse end markets • Glycols are used for the manufacture of polyester yarn, fibre, film and resin and as an automobile coolant • Bio-glycols cater to the beverage and food industry's packaging requirement of PET bottles and polyester film • Ethyl / Butyl glycol ethers and its ace
Slide 27: Growth Drivers
Growth Drivers High prospects of growth of industry sectors being serviced by IGL – Personal Care, Automotive, Packaging, Beverages, Oil & Gas, Home Care, Pharma, Nutraceuticals etc, Textiles – most expected to grow at near double digit or more Increasing consumer awareness and demand for sustai
Slide 28: Yearly financial Performance
Yearly financial Performance
Slide 29: 5-year Financial Trajectory - Consolidated
5-year Financial Trajectory - Consolidated In INR Cr Net Revenue (Excl. Discontinued Biz.) EBITDA (Excl. Discontinued Biz.) PAT (Excl. Discontinued Biz.) 330 2,744 2,890 288 283 277 2,332 109 75 FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 EBITDA (Incl. Discontinued Biz.) PAT (Incl
Slide 30: 5-year Financial Trajectory - Consolidated
5-year Financial Trajectory - Consolidated EBITDA Margin (%) (Excl. Discontinued Biz.) Net Margin (%) (Excl. Discontinued Biz.) RoE (%) 11.4% 12.1% 10.5% 19.2% 9.6% 4.7% 11.1% 11.3% 2.7% FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 EBITDA Margin (%) (Incl. Discontinued Biz.) PAT Ma
Slide 31: Sustainability, ESG and Certifications
Sustainability, ECG and Certifications
Slide 32: Sustainability, ESG
Sustainability, ESG Environment Stewardship • World’s first and largest producer of Bio-Based EO and its derivatives • Next Generation CarbonSmart products from emissions (fossil carbon) - collaboration with Transparent Accountable LanzaTech & consumer majors like Unilever and Lululemon • Environmen
Slide 33: Thank you
India Glycols Limited CIN: L24111UR1983PLC009097 EY LLP Ankur Jain Neha S Shroff Company Secretary & Compliance Officer neha.shroff@in.ey.com Rohit Anand Head office rohit.anand4@in.ey.com 2B, Sector-126, Noida Gautam Budh Nagar Uttar Pradesh 201304 Tel: +91-120-6860000, 3090100, 3090200 Fax: +91-12